Two-year follow-up study after treatment with lamivudine for chronic hepatitis B: Seven cases reported

Hepatology Research

Volumn 17, Issue 3, 2000, Pages 197-204

  Ide, Tatsuya ^a   Kumashiro, Ryukichi ^a   Suzuki, Hiroshi ^a   Tanikawa, Kyuichi ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fukuoka Prefectural University   (Japan)

Author keywords

Chronic hepatitis B; Lamivudine; Long term follow up

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBOXYETHYLGERMANIUM SESQUIOXIDE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NEOMINOPHAGEN C; URSODEOXYCHOLIC ACID; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DNA DETERMINATION; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; LONG TERM CARE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034020704     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(99)00075-3     Document Type: Article

References (16)

1. Doong S.L., Tsai C.H., Schinazi R.F., Liotta D.C., Cheng Y.C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. U.S.A. 88:1991;8495-8499.
2. Tyrrell D.L.J., Fischer K., Savani K., Ian W., Jewell L. Treatment of chimpanzees and ducks with lamivudine, 2′3′-dideoxy-3′-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera. Clin. Invest. Med. 16(Suppl. 4):1993;B77. (abstract).
3. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M.A. Preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1995;1657-1661.
4. Nevens F., Main J., Honkoop P. et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.
5. Lai C.L., Ching C.K., Tung A.K. et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 25:1997;241-244.
6. Andreone P., Caraceni P., Grazi G.L. et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J. Hepatol. 29:1998;985-989.
7. Grellier L., Mutimer D., Ahmed M. et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 348:1996;1212-1215.
8. Ben A.Z., Shmueli D., Mor E., Shapira Z., Tur K.R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation. 63:1997;393-396.
9. Lai C.L., Chien R.N., Leung N.W. et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:1998;61-68.
10. Tanikawa K., Ichida F., Suzuki H. et al. A long-term study of Lamivudine for chronic hepatitis B patients. Kantansui. 36:1998;597-611.
11. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
12. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
13. Dienstag JL, Schiff ER, Wright T, et al. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis Be-antigen (HBeAg) seroconversion (abstract). The American Association for the Study of Liver Diseases, DDW, 1998. p. A-1.
14. Liaw YF, Lai CL, Leung NWY, et al. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in asia (abstract). The American Association for the Study of Liver Diseases, DDW, 1998. p. A-1.
15. Honkoop P., Man R.A., Heiitjenk R.A., Schalm S.W. Hepatitis B reactivation after lamivudine. Lancet. 346:1995;1156-1157.
16. Leung N.W.Y., Lai C.L., Chang T.T. et al. Three year lamivudine therapy in chronic HBV. J. Hepatol. 30(suppl 1):1999;59.